Guidance in CV Risk management: How to deal with international guidelines?
Lecture held by Philip Barter, MD, University of Sydney, Sydney, Australia, during the CV Risk Master Class held on October 22, 2016 in Yogyakarta, Indonesia
- The overall educational objectives of the Cardiovascular Master Class were:
- To review the epidemiology and current guidelines on the diagnosis, management, and treatment of patients at increased CV risk in Indonesia
- To review new data on the pathophysiology of coronary artery disease and stroke and its relevance to treatment strategies and outcomes
- To understand the medical need for intensive lipid and hypertension management in patients at high CV risk, such as DM and metabolic syndrome.
- To understand the pharmacologic and clinical rationale for various treatment options in the patients with increased CV risk and integrate scientific evidence from key clinical trials into clinical practice
- Develop a consensus on practical guidelines for day-to-day management of high risk patients
This Master Class was endorsed and accredited by the Indonesian Cardiology Association
Prof Philip Barter, MD, Conjoint Professor of Medicine University of New South Wales -Sydney, Australia
The CV Risk Master Class was funded by an unrestricted educaional grant provided by Pfizer